Bibliography
- US Food and Drug Administration commemorates-30th-anniversary Orphan Drug Act web site Jan 17 2013
- Cote T, Kelkar A, Xu K, et al. Orphan products: an emerging trend in drug approvals. Nat Rev Drug Discovery 2010;9(1):84-5
- Phillips MI. Big pharma's new model in orphan drugs and rare diseases. Expert Opin Orphan Drugs 2013;1(1):1-3
- McCabe C, Claxton K, Tsuchiya A. Orphan drugs and the NHS: should we value rarity? Brit J Med 2005;331:1016-19
- Hyde R, Dobrovolny D. Orphan drug pricing and payer management in the United States: are we approaching the tipping point? Am Health Drug Benefits 2010;3(1):15-23
- DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: is biotech different? Manag Decis Econ 2007;28:496-79
- Scherer FM. R&D Costs and Productivity in Biopharmaceuticals. Regulatory Policy Program Working Paper RPP-2011-10. Mossavar-Rahmani Center for Business and Government, Harvard Kennedy School, Harvard University, Cambridge MA; 2011
- Meekings K, Williams C, Arrowsmith J. Orphan Drug Development: an economically viable strategy for biopharma R&D. Drug Discov Today 2012;17:660-4
- Hughes DA, Tunnange B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJ Med 2005;98:829-36
- Bernanke B S, Gertler M, Gilchrist S. The Financial Accelerator in a Quantitative Business Cycle Framework. In: Taylor JB, Woodford M, editors. Handbook of Macroeconomics. Elsevier; North-holland: 1999. 1(21), pp 1341-93
- Malkiel BG. The random walk guide to investing: ten rules for financial success. W.W.Norton; NewYork: 2003. 0-393-05854-9
- Scherbina, A. Asset Price Bubbles: A Selective Survey. International Monetary Fund 2013. IMF Working Paper: Institute for Capacity Development.
- Hughes-Wilson W, Palma A, Schuuman A, Simones S. Paying for the orphan drug system: break or bend? is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis 2012;7:7
- Paul D. Rare disease pricing- is it sustainable? Pharmaphorum 2013. Available from: http://www.pharmaphorum.com/2013/02/26/rare-disease-pricing-sustainable [Citied 12 March 2013]
- Schalamon J, Mayr JM, Hollwarth ME. Mortality and economics in short bowel syndrome. Best Pract Res Clin Gastroenterol 2003;17:931-42
- Jeppesen PB, Pertkiewicz M, Messing B, et al. Teduglutide reduces need for parenteral support among patients with short bowel sydrome with intestinal failure. Gastroenterology 2012;143(6):1473-81
- Friedman D, Urist M, Slifka S, Kugler B. NPS Pharmaceuticals: Novel Drugs, Untapped Markets; Init OW, PT $17. Morgan Stanley Research North America, Morgan Stanley & Co. LLC. October 3, 2012
- Swain S. The high cost of a cancer drug: an oncologist's view. Letter to the editor, Oct. 19, 2012. The New York Times. Available from: http://www.nytimes.com/2012/10/20/opinion/the-high-cost-of-a-cancer-drug-an-oncologists-view.html
- Burrow TA, Gregory AG. Velaglucerase alfa in the treatment of Gaucher disease type 1. Clin Investig 2011;1(2):285-93
- Herper M. The world's most expensive drugs. Forbes. 2010. Available from: http://www.forbes.com/2010/02/19/expensive-drugs-cost-business-healthcare-rare-diseases_slide.html